Review



phosphate buffered saline pbs  (Repligen Corp)


Bioz Verified Symbol Repligen Corp is a verified supplier
Bioz Manufacturer Symbol Repligen Corp manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Repligen Corp phosphate buffered saline pbs
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Phosphate Buffered Saline Pbs, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 377 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/pmc13054838-40-14-39?v=Repligen+Corp
    Average 95 stars, based on 377 article reviews
    phosphate buffered saline pbs - by Bioz Stars, 2026-06
    95/100 stars

    Images

    1) Product Images from "Systemic Inflammation Modulates Clearance and Drives Extra‐Hepatic Distribution of Extracellular Vesicles"

    Article Title: Systemic Inflammation Modulates Clearance and Drives Extra‐Hepatic Distribution of Extracellular Vesicles

    Journal: Journal of Extracellular Vesicles

    doi: 10.1002/jev2.70256

    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with PBS). Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; PBS, phosphate buffered saline; RLU, Relative Luminescent Units.
    Figure Legend Snippet: I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with PBS). Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; PBS, phosphate buffered saline; RLU, Relative Luminescent Units.

    Techniques Used: In Vivo, Injection, Clinical Proteomics, Control, Saline

    EV association with immune and non‐immune cells and biodistribution to various organs. % of EV positive (a) B cells; (b) CD4 T cells; (c) CD4− T cells; (d) myeloid cells; (e) macrophages; (f) neutrophils in the respective tissues: the liver, lungs, spleen, BM and blood; (g) hepatocytes and (h) plasma. Inflammation in mice was induced by a single dose of LPS at the concentration 5 mg/kg I.P. for 4 h before the administration of EVs. EVs were injected I.V. at 2 × 10 11 EVs/dose ( n = 3 mice) for 2 h. A control group (PBS) was used for the normalisation of the data ( n = 1–2). The immune cell panel was changed depending on the cell type analysis. Cells from each organ were stained for the hematopoietic differentiation marker CD45 (CD45+), macrophages (F4/80+), myeloid (GR1+/Cd11b+), B cells (B220), CD4 T cells (CD4+/CD3+), CD4− T cells (CD4−/CD3+), neutrophils (CD11b+/Ly6G+) and evaluated by Flow cytometry. Hepatocytes were gated after excluding immune cells. Cells associated with EVs were mNG positive. The values were normalised to untreated control mice and calculated as % mNG+ cells of viable or mNG+ cell counts/µL of plasma. Black—non‐primed healthy mice, pink—LPS‐primed mice. ND, non‐detectable. Statistical analysis was performed by a two‐tailed t test. *Represents p < 0.05, **represents p < 0.01, *** p < 0.0001 and **** p < 0.0001. The results represent mean±SD. BM, bone marrow; EV, extracellular vesicle; I.P., intraperitoneally; I.V., intravenously; LPS, lipopolysaccharide; mNG, mNeonGreen; PBS, phosphate buffered saline.
    Figure Legend Snippet: EV association with immune and non‐immune cells and biodistribution to various organs. % of EV positive (a) B cells; (b) CD4 T cells; (c) CD4− T cells; (d) myeloid cells; (e) macrophages; (f) neutrophils in the respective tissues: the liver, lungs, spleen, BM and blood; (g) hepatocytes and (h) plasma. Inflammation in mice was induced by a single dose of LPS at the concentration 5 mg/kg I.P. for 4 h before the administration of EVs. EVs were injected I.V. at 2 × 10 11 EVs/dose ( n = 3 mice) for 2 h. A control group (PBS) was used for the normalisation of the data ( n = 1–2). The immune cell panel was changed depending on the cell type analysis. Cells from each organ were stained for the hematopoietic differentiation marker CD45 (CD45+), macrophages (F4/80+), myeloid (GR1+/Cd11b+), B cells (B220), CD4 T cells (CD4+/CD3+), CD4− T cells (CD4−/CD3+), neutrophils (CD11b+/Ly6G+) and evaluated by Flow cytometry. Hepatocytes were gated after excluding immune cells. Cells associated with EVs were mNG positive. The values were normalised to untreated control mice and calculated as % mNG+ cells of viable or mNG+ cell counts/µL of plasma. Black—non‐primed healthy mice, pink—LPS‐primed mice. ND, non‐detectable. Statistical analysis was performed by a two‐tailed t test. *Represents p < 0.05, **represents p < 0.01, *** p < 0.0001 and **** p < 0.0001. The results represent mean±SD. BM, bone marrow; EV, extracellular vesicle; I.P., intraperitoneally; I.V., intravenously; LPS, lipopolysaccharide; mNG, mNeonGreen; PBS, phosphate buffered saline.

    Techniques Used: Clinical Proteomics, Concentration Assay, Injection, Control, Staining, Marker, Flow Cytometry, Two Tailed Test, Saline



    Similar Products

    95
    Repligen Corp phosphate buffered saline pbs
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Phosphate Buffered Saline Pbs, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/pmc13054838-40-14-39?v=Repligen+Corp
    Average 95 stars, based on 1 article reviews
    phosphate buffered saline pbs - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    Repligen Corp tangential flow filtration tff
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Tangential Flow Filtration Tff, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/pmc13054838-40-29-39?v=Repligen+Corp
    Average 95 stars, based on 1 article reviews
    tangential flow filtration tff - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    Repligen Corp krosflo research iii tangential flow filtration tff system
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Krosflo Research Iii Tangential Flow Filtration Tff System, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/bio_rxiv__64898__2026__03__09__710050-124-9-17?v=Repligen+Corp
    Average 95 stars, based on 1 article reviews
    krosflo research iii tangential flow filtration tff system - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    Repligen Corp spectrum hollow fiber filter
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Spectrum Hollow Fiber Filter, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/10__1016_slash_j__celbio__2026__100410-342-9-8?v=Repligen+Corp
    Average 95 stars, based on 1 article reviews
    spectrum hollow fiber filter - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    Repligen Corp cellulose dialysis tubing
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Cellulose Dialysis Tubing, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/us12533630-346-2-5?v=Repligen+Corp
    Average 95 stars, based on 1 article reviews
    cellulose dialysis tubing - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    Repligen Corp kilodaltons
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Kilodaltons, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/us12509501-1739-17-19?v=Repligen+Corp
    Average 95 stars, based on 1 article reviews
    kilodaltons - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    Repligen Corp spectra por 2 cellulose dialysis membrane
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Spectra Por 2 Cellulose Dialysis Membrane, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/pmc12787833-170-1-22?v=Repligen+Corp
    Average 95 stars, based on 1 article reviews
    spectra por 2 cellulose dialysis membrane - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    Repligen Corp corporation waltham
    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with <t>PBS).</t> Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; <t>PBS,</t> <t>phosphate</t> buffered saline; RLU, Relative Luminescent Units.
    Corporation Waltham, supplied by Repligen Corp, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/spectrum+hollow+fiber/10__3390_slash_polym18010086-106-21-20?v=Repligen+Corp
    Average 95 stars, based on 1 article reviews
    corporation waltham - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    Image Search Results


    I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with PBS). Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; PBS, phosphate buffered saline; RLU, Relative Luminescent Units.

    Journal: Journal of Extracellular Vesicles

    Article Title: Systemic Inflammation Modulates Clearance and Drives Extra‐Hepatic Distribution of Extracellular Vesicles

    doi: 10.1002/jev2.70256

    Figure Lengend Snippet: I.P. administered EV biodistribution in tissues. (a) Schematic workflow for studying biodistribution of exogenous EVs in vivo. (b–g) EV accumulation in the respective tissues was quantified as % of injected dose—% ID (organ/mouse) or % ID/mL of plasma employing the bioluminescent assay. The numbers display RLU fold change in EV accumulation in LPS‐primed mice over the healthy mice in the brain (b), lungs (c), liver (d), spleen (e), kidney (f) and plasma (g). The acute inflammation was induced by a single dose of LPS at 5 mg/kg 4 h before the EV administration. Based on NTA measurements, EVs were injected I.P. at 1 × 10 11 EVs/dose ( n = 4–5 mice) for 0.5, 2, 4 and 24 h before the blood and tissue collection according to the Methods section for the subsequent analysis. A control group was used for the normalisation of the data ( n = 4). Black—non‐primed healthy mice, pink—LPS‐primed mice. Arrows indicate the fold change in EV accumulation in LPS‐primed mice over healthy mice (primed with PBS). Statistical analysis was performed by two‐way ANOVA. ** Represents p < 0.01, *** p < 0.001 and **** p < 0.0001. The results represent mean ± SD. EV, extracellular vesicle; ID, injected dose; I.P., intraperitoneally; LPS, lipopolysaccharide; NTA, nanoparticle tracking analysis; PBS, phosphate buffered saline; RLU, Relative Luminescent Units.

    Article Snippet: EVs from pre‐cleared CM were further subjected to diafiltration with double volume of pre‐filtered phosphate buffered saline (PBS) and concentrated to the volume of about 50 mL by using tangential flow filtration (TFF) with the KrosFlo KR2i TFF System (Repligen, USA) equipped with modified polyethersulfone (mPES) hollow fibre filters with 300 kDa membrane pore size (MidiKros, 370 cm 2 surface area, SpectrumLabs, D06‐E300‐05‐N) as a cutoff membrane at a flow rate of 100 mL/min (transmembrane pressure at 3.0 psi and shear rate at 3700 s −1 ) as described previously (Corso et al. ).

    Techniques: In Vivo, Injection, Clinical Proteomics, Control, Saline

    EV association with immune and non‐immune cells and biodistribution to various organs. % of EV positive (a) B cells; (b) CD4 T cells; (c) CD4− T cells; (d) myeloid cells; (e) macrophages; (f) neutrophils in the respective tissues: the liver, lungs, spleen, BM and blood; (g) hepatocytes and (h) plasma. Inflammation in mice was induced by a single dose of LPS at the concentration 5 mg/kg I.P. for 4 h before the administration of EVs. EVs were injected I.V. at 2 × 10 11 EVs/dose ( n = 3 mice) for 2 h. A control group (PBS) was used for the normalisation of the data ( n = 1–2). The immune cell panel was changed depending on the cell type analysis. Cells from each organ were stained for the hematopoietic differentiation marker CD45 (CD45+), macrophages (F4/80+), myeloid (GR1+/Cd11b+), B cells (B220), CD4 T cells (CD4+/CD3+), CD4− T cells (CD4−/CD3+), neutrophils (CD11b+/Ly6G+) and evaluated by Flow cytometry. Hepatocytes were gated after excluding immune cells. Cells associated with EVs were mNG positive. The values were normalised to untreated control mice and calculated as % mNG+ cells of viable or mNG+ cell counts/µL of plasma. Black—non‐primed healthy mice, pink—LPS‐primed mice. ND, non‐detectable. Statistical analysis was performed by a two‐tailed t test. *Represents p < 0.05, **represents p < 0.01, *** p < 0.0001 and **** p < 0.0001. The results represent mean±SD. BM, bone marrow; EV, extracellular vesicle; I.P., intraperitoneally; I.V., intravenously; LPS, lipopolysaccharide; mNG, mNeonGreen; PBS, phosphate buffered saline.

    Journal: Journal of Extracellular Vesicles

    Article Title: Systemic Inflammation Modulates Clearance and Drives Extra‐Hepatic Distribution of Extracellular Vesicles

    doi: 10.1002/jev2.70256

    Figure Lengend Snippet: EV association with immune and non‐immune cells and biodistribution to various organs. % of EV positive (a) B cells; (b) CD4 T cells; (c) CD4− T cells; (d) myeloid cells; (e) macrophages; (f) neutrophils in the respective tissues: the liver, lungs, spleen, BM and blood; (g) hepatocytes and (h) plasma. Inflammation in mice was induced by a single dose of LPS at the concentration 5 mg/kg I.P. for 4 h before the administration of EVs. EVs were injected I.V. at 2 × 10 11 EVs/dose ( n = 3 mice) for 2 h. A control group (PBS) was used for the normalisation of the data ( n = 1–2). The immune cell panel was changed depending on the cell type analysis. Cells from each organ were stained for the hematopoietic differentiation marker CD45 (CD45+), macrophages (F4/80+), myeloid (GR1+/Cd11b+), B cells (B220), CD4 T cells (CD4+/CD3+), CD4− T cells (CD4−/CD3+), neutrophils (CD11b+/Ly6G+) and evaluated by Flow cytometry. Hepatocytes were gated after excluding immune cells. Cells associated with EVs were mNG positive. The values were normalised to untreated control mice and calculated as % mNG+ cells of viable or mNG+ cell counts/µL of plasma. Black—non‐primed healthy mice, pink—LPS‐primed mice. ND, non‐detectable. Statistical analysis was performed by a two‐tailed t test. *Represents p < 0.05, **represents p < 0.01, *** p < 0.0001 and **** p < 0.0001. The results represent mean±SD. BM, bone marrow; EV, extracellular vesicle; I.P., intraperitoneally; I.V., intravenously; LPS, lipopolysaccharide; mNG, mNeonGreen; PBS, phosphate buffered saline.

    Article Snippet: EVs from pre‐cleared CM were further subjected to diafiltration with double volume of pre‐filtered phosphate buffered saline (PBS) and concentrated to the volume of about 50 mL by using tangential flow filtration (TFF) with the KrosFlo KR2i TFF System (Repligen, USA) equipped with modified polyethersulfone (mPES) hollow fibre filters with 300 kDa membrane pore size (MidiKros, 370 cm 2 surface area, SpectrumLabs, D06‐E300‐05‐N) as a cutoff membrane at a flow rate of 100 mL/min (transmembrane pressure at 3.0 psi and shear rate at 3700 s −1 ) as described previously (Corso et al. ).

    Techniques: Clinical Proteomics, Concentration Assay, Injection, Control, Staining, Marker, Flow Cytometry, Two Tailed Test, Saline